Evofem Biosciences, Inc. (EVFM) |
| 0.009 0.001 (5.88%) 04-15 16:00 |
| Open: | 0.0087 |
| High: | 0.009 |
| Low: | 0.0087 |
| Volume: | 20,000 |
| Market Cap: | 1(M) |
| PE Ratio: | -0.18 |
| Exchange: | Other OTC |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 5.91 |
| Resistance 1: | 5.06 |
| Pivot price: | 4.96 |
| Support 1: | 4.93 |
| Support 2: | 4.84 |
| 52w High: | 0.02 |
| 52w Low: | 0.007 |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
| EPS | 0.200 |
| Book Value | 5.970 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.836 |
| Profit Margin (%) | 61.29 |
| Operating Margin (%) | 86.41 |
| Return on Assets (ttm) | 4.8 |
| Return on Equity (ttm) | 6.4 |
Thu, 19 Mar 2026
Evofem (NASDAQ: EVFM) ends Windtree PHEXXI supply deal without termination fees - Stock Titan
Wed, 11 Mar 2026
Evofem (OTC: EVFM) posts 2025 profit as Q4 sales jump 35% - Stock Titan
Wed, 11 Mar 2026
Evofem Reports Fifth Consecutive Year of Net Sales Growth - Business Wire
Fri, 23 Jan 2026
Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women’s Health at Fierce JPM Week 2026 - Business Wire
Thu, 13 Nov 2025
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update - PR Newswire
Mon, 20 Oct 2025
Evofem Announces Voting Results from Special Meeting of Stockholders - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |